Date Title Description PDF
15 Mar 2022 On significant placements in financial instruments Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
14 Mar 2022 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
23 Feb 2022 On business and financial situation The Company releases the press release related to the full year 2021 financial results Download
23 Feb 2022 On business and financial situation The Company releases the full year 2021 financial results presentation Download
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download

Pages

Date Title Description PDF
28 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 21 March 2022 and 25 March 2022 Download
21 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 March 2022 and 18 March 2022 Download
14 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 March 2022 and 11 March 2022 Download
07 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 28 February 2022 and 4 March 2022 Download
28 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages